Navigation Links
Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/4/2011

PRINCETON, N.J., Jan. 4, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the 29th Annual J.P. Morgan Healthcare Conference to be held January 10-13, 2011 at the Westin St. Francis Hotel, San Francisco, CA. Schaefer Price, President and Chief Executive Officer, will provide an overview of the company on Wednesday, January 12, 2011 at 9:00 AM (PT).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have four clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in tw
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ Insulin ... announced public offering of common stock have exercised their ... common stock at a price to the public of ... the offering is expected to be $64.8 million, after ...
(Date:3/2/2015)... , March 2, 2015 For the past 15 years, ... per year in the U.S. alone (U.S. Census Bureau 2012). Of ... minor fender benders BUT there are quite a few where the ... intrusion, which can obstruct the seatbelt release button or occupant injury. ... in any serious accidents in their lifetime but may still be ...
(Date:3/2/2015)... -- Leading patient advocacy organization Fight Colorectal Cancer and ... One Million Strong campaign to spotlight colorectal ... funds for colorectal cancer education, research and prevention while ... living in the United States ... every day. Showing Strength for Colorectal Cancer ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 3New SuperVizor, an Automobile Escape Tool, Ensures the Safety of Drivers and Passengers on the Road 2Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 2Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 3Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 4Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 5
... , July 25, 2011 Pharmasset, Inc. (Nasdaq: ... to discovering, developing, and commercializing novel drugs to treat ... for the quarter ended June 30, 2011. ... quarter ended June 30, 2011 compared to $0.2 million ...
... VR Business Sales, Mergers & Acquisitions Charlotte, N.C. ... of Salisbury, NC.  This durable medical equipment provider specializes ... manual and power wheelchairs and scooters. "Penrod ... equipment providers I,ve seen.  The business generated a lot ...
Cached Medicine Technology:Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 2Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 3Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 4Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 5
(Date:3/2/2015)... 2015 New York singer/songwriter Richie ... delivering a plenary address entitled Finding the Music ... of Healing and Recovery at this year’s National ... Executive Summit (BHES).     , With more than 300 ... been recorded by some of the biggest names ...
(Date:3/2/2015)... The minimally invasive surgical instruments ... of 6.1% to reach $14,133.0 million by 2019 ... such as advantages of minimally invasive surgeries over ... minimally invasive surgeries and increasing number of surgical ... global minimally invasive surgical instruments market. , For ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Atlantic Information ... of AIS’s Directory of Health Plans: 2015 , ... available on the U.S. health plan market, with enrollment ... the United States. , Available as a printed ... of enrollment trends in quick-view tables and charts, as ...
(Date:3/2/2015)... March 02, 2015 In light of ... anticoagulant Xarelto (rivaroxaban) tablets, Ford & Associates ... be helpful for future users, but may come too ... from taking the drug. The FDA has now included ... Adverse Reactions on Xarelto's label. The term “cytolytic hepatitis” ...
(Date:3/2/2015)... March 02, 2015 ProvidaStaff ... for its educational healthcare division to EDU Healthcare ... healthcare services to school systems and students nationwide. , ... to school districts throughout the country,” said Angela M. ... be a better organization and the introduction of EDU ...
Breaking Medicine News(10 mins):Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3
... Children's Research Hospital have created a mouse model of a ... about //the gene therapy used to treat children that caused ... combined immunodeficiency (XSCID), is set into action by a mutation ... system from forming B and T lymphocytes. ...
... The manner of transmission of mosquito-borne viruses is well known; ... make an entry into the blood stream. But what happens ... of its victim. Researchers led by a Howard Hughes Medical ... point at a genetic element which helps the dengue virus ...
... study led by Volker Heussler of the Bernhard Nocht Institute ... malarial //parasite avoids the immune system by killing the liver ... that after infecting man, malarial parasites head to the liver ... was not known how the parasite avoids the immune system. ...
... gene which was identified by Professor Sir David Lane of ... gene using the mice model shows that the gene keeps ... Donehower of Baylor College of Medicine in Houston created some ... cancer. In another set he modified the gene and the ...
... Giving up your regular late-night snack may be hard, and ... change an area of the brain to expect the food// ... discovered. ,By training mice to eat at a ... turns on body-clock genes in a particular area of the ...
... isn't limited to soldiers or witnesses of a horrifying event. ... or heart surgery. Not only does PTSD cause emotional// and ... progression of heart disease, reports the August issue of the ... PTSD is that the trauma comes from within. Sufferers are ...
Cached Medicine News:Health News:Discovery In "Bubble Boy" Disease Gene Therapy 2Health News:Discovery In "Bubble Boy" Disease Gene Therapy 3Health News:Discovery In "Bubble Boy" Disease Gene Therapy 4Health News:The Dengue Virus Unplugged 2Health News:The Dengue Virus Unplugged 3Health News:Timing of Food Consumption Activates Genes in Specific Brain Area 2
For the quantitative in vitro determination of IgE in Human Serum or Plasma....
For the quantitative in vitro determination of IgG in serum and plasma. This product is suitable for use on the Aeroset...
Latex-enhanced immunoturbidimetric assay for the quantitative in vitro determination of C-reactive protein in serum and plasma...
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of CRP in serum....
Medicine Products: